Warning letter
Chemco Corporation: warning letter of Apr 7, 2026
FDA warning letter 721592 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 721592 |
|---|---|
| Company | Chemco Corporation |
| Subject | Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated |
| Issue date | Apr 7, 2026 |
| Posted date | Apr 14, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 310.545(a)(22)(iii), 201.10(c)(4), 201.66, 201.128, 207.77(a), 211.22, 211.34, 211.67(a), 211.84(d)(1), 310.545, 330 |
| Inspection city | Miami Lakes |
| Inspection ZIP | 33014 |
| Inspection start date | Aug 11, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: